Press Releases May 12, 2026 04:34 PM

Vornado JV Completes $161 Million Refinancing of 61 Ninth Avenue

Vornado JV refinances 61 Ninth Avenue property with $161 million loan amid rising interest rates

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
VNO

Vornado Realty Trust’s joint venture secured a $161 million refinancing loan for its 61 Ninth Avenue property in Manhattan, replacing an existing $155 million loan with a longer maturity and higher interest rates tied to SOFR. The property is fully leased to major tenants Aetna and Starbucks, and the new loan matures in March 2029 with escalating margins over SOFR.

Vornado JV Completes $161 Million Refinancing of 61 Ninth Avenue
VNO
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Vornado's JV refinanced a $161 million loan for 61 Ninth Avenue property, replacing a $155 million loan with longer maturity.
  • Interest rates on the new loan increased from previous levels, reflecting rising borrowing costs (SOFR plus increasing spreads).
  • The property is fully leased to well-known tenants, indicating stable cash flow from the asset.

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Vornado Realty Trust (NYSE:VNO) announced today that its 45.1% owned joint venture has completed a $161 million refinancing of 61 Ninth Avenue, a 194,000 square foot office and retail property in the Meatpacking district of Manhattan, which is fully leased to Aetna and Starbucks. The interest only loan, which matures in March 2029, as fully extended, carries a rate of SOFR plus 3.00% for the first year, SOFR plus 3.35% for the second year and SOFR plus 3.85% for the remainder of the term.

The loan replaces the previous $155 million loan that bore interest at SOFR plus 2.45% and was scheduled to mature in November 2026.

Vornado Realty Trust is a fully-integrated equity real estate investment trust.

CONTACT

Thomas J. Sanelli
(212) 894-7000

Certain statements contained herein may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance. They represent our intentions, plans, expectations and beliefs and are subject to numerous assumptions, risks and uncertainties. Our future results, financial condition and business may differ materially from those expressed in these forward-looking statements. You can find many of these statements by looking for words such as "approximates," "believes," "expects," "anticipates," "estimates," "intends," "plans," "would," "may" or other similar expressions in this press release. For a discussion of factors that could materially affect the outcome of our forward-looking statements and our future results and financial condition, see “Risk Factors” in Part I, Item 1A, of our Annual Report on Form 10-K for the year ended December 31, 2025. Currently, some of the factors are interest rate fluctuations and effects of inflation on our business, financial condition, results of operations, cash flows, operating performance and the effect that these factors have had and may continue to have on our tenants, the global, national, regional and local economies and financial markets and the real estate market in general.


Risks

  • Rising interest rates increase borrowing costs and could pressure cash flows and financial performance.
  • Economic or market downturns could impact tenants' ability to pay rent, affecting property income.
  • General real estate market uncertainty amid inflation and macroeconomic shifts may affect property valuation and liquidity.

More from Press Releases

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 Jun 14, 2026 Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026 Jun 14, 2026 Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control Jun 14, 2026 Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026